Oculis Announce a $100 Million Capital Increase
Share this article
Swiss-Icelandic ophthalmic laboratory Oculis announced a $100 million capital increase on Friday. The financial operation was carried out through an oversubscribed offering of 5 million shares at $20 each.
Born in 2017 in Iceland, the company then expanded to the EPFL Innovation Park before setting up its headquarters in Zug. It has offices in Lausanne, Boston and Reykjavik. Its listing on the Nasdaq in New York began in March 2023.
Oculis announced on 14 February 2025 the pricing of an underwritten offering of 5,000,000 of its ordinary shares at a price of $20.00 per share, for total gross proceeds of $100 million. Proceeds will be used to advance and accelerate its clinical development pipeline, particularly the development of its novel neuroprotective clinical candidate Privosegtor (OCS-05).
This Offering follows the release of recent groundbreaking data from the Phase 2 ACUITY trial of OCS-05 (Privosegtor), which has the potential to be the first neuroprotective treatment in ophthalmology, in patients with acute optic neuritis. Data showed OCS-05 met the primary endpoint of safety, in addition to key secondary endpoints that highlighted its neuroprotective structural benefits and the ability to improve visual function in this disease area, with potential to expand across multiple ophthalmic and neurological conditions, including glaucoma.
Source: Oculis PR. 📸 Oculis